Live feed
Filing
SCHEDULE 13D
SCHEDULE 13D0001477932-25-001180·Matinas BioPharma Holdings, Inc.
Schedule 13D ownership disclosure
MATINAS BIOPHARMA HLDGS INC
Common Stock, $0.0001 par value per share · CUSIP: 576810303
Event date: 2025-02-13
Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.
- Filing-level shares
- Unavailable
- Percent of class
- Unavailable
- Pembroke & Partners LLCReported CIK 0002056785
Shares: 1,016,888 · Class: 19.99%
- Robert J. EideReported CIK 0001181955
Shares: 1,018,388 · Class: 20.0%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001477932-25-001180
- Form type
- SCHEDULE 13D
- Filer
- Matinas BioPharma Holdings, Inc.
- CIK
- CIK 1582554
- Filed
- Feb 21, 2025
- Reporting period
- Feb 13, 2025
- Description
- Schedule 13D beneficial ownership